Enact (ACT) Price, Holdings, & News

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enact in the last year. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" ACT shares.
View ACT analyst ratings or view top-rated stocks.

0 equities research analysts have issued 1 year price objectives for Enact's stock. Their ACT share price targets range from $0.00 to $0.00. On average, they expect the company's share price to reach $0.00 in the next year. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for ACT or view top-rated stocks among Wall Street analysts.

Enact's stock was trading at $28.89 at the beginning of the year. Since then, ACT stock has increased by 3.5% and is now trading at $29.91.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ACT earnings forecast.

Enact will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Enact Holdings, Inc. (NASDAQ:ACT) issued its earnings results on Tuesday, February, 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.08. The firm earned $296.19 million during the quarter, compared to analyst estimates of $303.58 million. Enact had a trailing twelve-month return on equity of 15.23% and a net margin of 57.69%. During the same quarter in the previous year, the business earned $0.90 EPS.

Enact declared a quarterly dividend on Tuesday, February 20th. Stockholders of record on Wednesday, February 28th will be given a dividend of $0.16 per share on Wednesday, March 13th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 2.14%. The ex-dividend date is Tuesday, February 27th.
Read our dividend analysis for ACT.

Enact is a equity fund issued by AdvisorShares. ACT focuses on theme investments. The fund's investments total to approximately $12.40 million assets under management.

Enact's management fee is 0.60% and has other expenses of 0.31%. However, ACT has a fee waiver of -0.16% to reimburse the expenses. The net expense ratio for ACT is 0.75%.

12 employees have rated Enact Chief Executive Officer Dave Page on Glassdoor.com. Dave Page has an approval rating of 100% among the company's employees. This puts Dave Page in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enact investors own include Cara Therapeutics (CARA), Cronos Group (CRON), Innovative Industrial Properties (IIPR), Amplify Alternative Harvest ETF (MJ), Organigram (OGI), Tilray (TLRY), Zynerba Pharmaceuticals (ZYNE) and

Enact (ACT) raised $253 million in an initial public offering on Thursday, September 16th 2021. The company issued 13,310,400 shares at $19.00 per share.

Enact's stock is owned by many different retail and institutional investors. Top institutional shareholders include Denali Advisors LLC (0.11%), Measured Wealth Private Client Group LLC (0.02%), Renaissance Capital LLC (0.01%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Anne G Waleski, Brian Gould, Dominic James Addesso, Genworth Holdings, Inc, Hardin Dean Mitchell and Rohit Gupta.
View institutional ownership trends.

Shares of ACT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.